Coastline Trust Co Has $5.31 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Coastline Trust Co decreased its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 6.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,030 shares of the medical research company's stock after selling 1,207 shares during the period. Coastline Trust Co's holdings in Amgen were worth $5,306,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Amgen by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 52,721,795 shares of the medical research company's stock valued at $13,741,409,000 after purchasing an additional 339,522 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Amgen by 25.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock worth $3,441,909,000 after purchasing an additional 2,672,975 shares during the period. Geode Capital Management LLC raised its position in shares of Amgen by 2.9% during the fourth quarter. Geode Capital Management LLC now owns 12,475,032 shares of the medical research company's stock valued at $3,245,881,000 after buying an additional 352,143 shares during the last quarter. Capital International Investors lifted its stake in shares of Amgen by 40.1% in the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock valued at $3,182,843,000 after buying an additional 3,495,503 shares during the period. Finally, Capital World Investors grew its position in Amgen by 1,292.0% during the fourth quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock worth $1,693,042,000 after buying an additional 6,029,058 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

AMGN traded up $1.40 during trading on Thursday, hitting $298.25. The company's stock had a trading volume of 1,518,529 shares, compared to its average volume of 2,842,825. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 8.70. The stock has a market capitalization of $160.37 billion, a price-to-earnings ratio of 27.21, a price-to-earnings-growth ratio of 2.68 and a beta of 0.49. The firm's 50 day moving average price is $282.12 and its two-hundred day moving average price is $286.57. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The company had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. During the same period last year, the company posted $3.96 earnings per share. The firm's quarterly revenue was up 9.4% compared to the same quarter last year. Sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the business's stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the transaction, the senior vice president directly owned 8,162 shares of the company's stock, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.76% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on AMGN. Guggenheim initiated coverage on Amgen in a report on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 price target for the company. UBS Group restated a "neutral" rating and set a $315.00 price objective (down from $319.00) on shares of Amgen in a research report on Friday, May 2nd. William Blair reaffirmed an "outperform" rating on shares of Amgen in a research report on Tuesday, June 24th. Cantor Fitzgerald reiterated a "neutral" rating and set a $305.00 price target on shares of Amgen in a research note on Tuesday, June 24th. Finally, Mizuho increased their price objective on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research note on Wednesday, May 7th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Amgen presently has an average rating of "Hold" and a consensus price target of $307.82.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.